Biology Faculty Articles

Title

Mitochondrial DNA Haplogroups Influence Lipoatrophy After Highly Active Antiretroviral Therapy

Document Type

Article

Publication Date

6-1-2009

Publication Title

Journal of Acquired Immune Deficiency Syndromes

Keywords

Lipoatrophy, Mitochondrial haplogroup, Mitochondrial toxicity, NRTI

ISSN

1525-4135

Volume

51

Issue/No.

2

First Page

111

Last Page

116

Abstract

Although highly active antiretroviral therapy (HAART) has been extremely effective in lowering AIDS incidence among patients infected with HIV, certain drugs included in HAART can cause serious mitochondrial toxicities. One of the most frequent adverse events is lipoatrophy, which is the loss of subcutaneous fat in the face, arms, buttocks, and/or legs as an adverse reaction to nucleoside reverse transcriptase inhibitors. The clinical symptoms of lipoatrophy resemble those of inherited mitochondrial diseases, which suggest that host mitochondrial genotype may play a role in susceptibility. We analyzed the association between mitochondrial haplogroup and severity of lipoatrophy in HIV-infected European American patients on HAART in the Multicenter AIDS cohort Study and found that mitochondrial haplogroup H was strongly associated with increased atrophy [arms: P = 0.007, odds ratio (OR) = 1.77, 95% confidence interval (CI) = 1.17 to 2.69; legs: P = 0.037, OR = 1.54, 95% CI = 1.03 to 2.31; and buttocks: P = 0.10, OR = 1.41 95% CI = 0.94 to 2.12]. We also saw borderline significance for haplogroup T as protective against lipoatrophy (P = 0.05, OR = 0.52, 95% CI = 0.20 to 1.00). These data suggest that mitochondrial DNA haplogroup may influence the propensity for lipoatrophy in patients receiving nucleoside reverse transcriptase inhibitors.

Comments

©2009 Lippincott Williams & Wilkins

Additional Comments

National Institutes of Health grant #s: UO1-AI-35042, 5-MO1-RR-00722, UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, UO1-AI-35041, M01 RR00425, AG24373, DK73691, NS21328, AG16573, AG25638; Spanish Fondo de Investigacion Sanitaria grant #s: FIS-PI08-0264, DGA-PM-083/2008

ORCID ID

0000-0001-7353-8301

ResearcherID

N-1726-2015

This document is currently not available here.

Find in your library

Share

COinS